Amid heightened public concern, the cost of prescription drugs is the focus of renewed attention by the Trump administration and lawmakers in Congress and state capitals. Proposed actions range from sweeping health care system changes to targeted initiatives that could affect Medicare, Medicaid and private insurance. See KFF’s research, analysis and public opinion data, as well as Kaiser Health News’ journalism, related to prescription drugs and their costs.
Featured Prescription Drugs Resources
KFF Health Tracking Poll – October 2019: Health Care In The Democratic Debates, Congress, And The Courts
This poll examines health care issues in the Democratic presidential primary , government negotiation of prescription drug prices, party trust on health care, Medicare-for-all, and the pending Texas v. US lawsuit affecting the Affordable Care Act and pre-existing condition protections.
Poll Finding See More
Related Prescription Drugs Resources
- 10 FAQs on Prescription Drug Importation
- Pricing and Payment for Medicaid Prescription Drugs
- Management and Delivery of the Medicaid Pharmacy Benefit
- Understanding the Medicaid Prescription Drug Rebate Program
- A Look at Recent Proposals to Control Drug Spending by Medicare and its Beneficiaries
- Kaiser Health News Coverage of Prescription Drug Issues
- What are the recent and forecasted trends in prescription drug spending?
- What’s the Latest on Medicare Drug Price Negotiations?
- How Will The Medicare Part D Benefit Change Under Current Law and Leading Proposals?
- Medicaid’s Prescription Drug Benefit: Key Facts
- Public Opinion on Prescription Drugs and Their Prices
- Prescription Drug Rebates, Explained
- What Are Recent Trends and Characteristics of Workers with High Drug Spending?
- Snapshots of Recent State Initiatives in Medicaid Prescription Drug Cost Control
- 10 Essential Facts About Medicare and Prescription Drug Spending
- Utilization and Spending Trends in Medicaid Outpatient Prescription Drugs
- How Does Prescription Drug Spending and Use Compare Across Large Employer Plans, Medicare Part D, and Medicaid?
This quick primer explains the similarities and differences among major proposals to lower prescription drug costs introduced by House Democrats, the Senate Finance Committee, and the Trump Administration as of December 2019.
Slideshow See More
- view as grid
- view as list
Using Medicaid State Drug Utilization Data, this brief presents the 50 most costly drugs before rebates used by the Medicaid program over the January 2014 through June 2015 period. It then examines reasons why these drugs are so costly; explores case studies on opioids, hepatitis C drugs, and the drug Abilify; and considers policy implications.
Most Americans Say Federal and State Governments Are Not Doing Enough to Combat Prescription Painkiller and Heroin Abuse; Large Majorities Believe Wide Range of Strategies Would be Effective
As the White House and Congress continue to debate new funding and other actions to address the nation’s opioid epidemic, the latest Kaiser Health Tracking Poll finds that most Americans believe the federal government is not doing enough to combat the recent increases in the number of people who are…
This Visualizing Health Policy infographic with JAMA spotlights public opinion on health reform in the United States as of 2017, including priorities and views of the Affordable Care Act (also known as Obamacare) and its provisions.
Poll: Majorities of Democrats, Republicans and Independents Support Actions to Lower Drug Costs, Including Allowing Americans to Buy Drugs from Canada
When asked about a series of health care priorities facing President Trump and Congress, six in 10 Americans (60%) identify lowering the cost of prescription drugs as a “top priority” for President Trump and Congress – including majorities of Democrats, independents, and Republicans. The latest Kaiser Health Tracking Survey examines…
Medicaid Moving Ahead in Uncertain Times: Results from a 50-State Medicaid Budget Survey for State Fiscal Years 2017 and 2018
This report provides an in-depth examination of the changes taking place in Medicaid programs across the country. Report findings are drawn from the annual budget survey of Medicaid officials in all 50 states and the District of Columbia conducted by the Kaiser Family Foundation (KFF) and Health Management Associates (HMA), in collaboration with the National Association of Medicaid Directors (NAMD). This report examines the reforms, policy changes, and initiatives that occurred in FY 2017 and those adopted for implementation for FY 2018 (which began for most states on July 1, 2017). Key areas covered include changes in eligibility and enrollment, managed care and delivery system reforms, long-term services and supports, provider payment rates and taxes, covered benefits (including prescription drug policies), and opioid harm reduction strategies.
Six Months ahead of the Midterm Elections, Democratic and Republican Voters’ Views about President Trump Outweigh their Views on Issues, Including Health Care
Who are the “Health Care Voters”? Mostly Women, and Mostly Planning to Vote Democratic As primary season for the 2018 midterm elections heats up, the latest Kaiser Family Foundation poll suggests the elections are shaping up more as a referendum on President Trump than on health care or any other…
This issue brief examines how the Trump Administration proposals to lower drug costs described in the Administration’s Blueprint affect Medicaid. These include proposals to change the Medicaid Drug Rebate Program, as well as other approaches.
This data note examines the latest data and trends in the Medicare Part D coverage gap, where enrollees must pay a greater share of their prescription drug costs. The note includes data about how many Part D enrollees reached the coverage gap, their average out-of-pocket spending, the value of manufacturer discounts, and recent and proposed changes affecting out-of-pocket costs for Part D enrollees who reach the gap.